Replimune (REPL) stock plunges as the company seeks layoffs following the FDA rejection of its cancer drug RP1 for melanoma.
Having split its first two games of the season, the Liverpool boys lacrosse team would learn a lot more about its strengths and weaknesses from what was supposed to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results